Tectonic Therapeutic, Inc. (TECX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tectonic Therapeutic, Inc. (TECX) has a cash flow conversion efficiency ratio of -0.080x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.41 Million) by net assets ($230.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Tectonic Therapeutic, Inc. worth for the company's overall valuation and market capitalisation.
Tectonic Therapeutic, Inc. - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Tectonic Therapeutic, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tectonic Therapeutic, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tectonic Therapeutic, Inc. ranked by their cash flow conversion efficiency. See TECX operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unizyx Holding Corp
TW:3704
|
-0.141x |
|
Guangdong Dp Co Ltd
SHE:300808
|
0.011x |
|
Capital Bancorp
NASDAQ:CBNK
|
0.053x |
|
Sunrise Energy Metals Ltd
AU:SRL
|
-0.278x |
|
AGI Greenpac Limited
NSE:AGI
|
-0.035x |
|
Jiangsu Hengshang Energy Conservation Technology Co. Ltd. A
SHG:603137
|
N/A |
|
OPTHEA LTD (SP.ADR/8)
F:UKJ2
|
N/A |
|
Kunshan Asia Aroma Corp. Ltd.
SHE:301220
|
0.002x |
Annual Cash Flow Conversion Efficiency for Tectonic Therapeutic, Inc. (2016–2025)
The table below shows the annual cash flow conversion efficiency of Tectonic Therapeutic, Inc. from 2016 to 2025. View Tectonic Therapeutic, Inc. share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $251.33 Million | $-60.08 Million | -0.239x | +43.04% |
| 2024-12-31 | $140.78 Million | $-59.08 Million | -0.420x | -187.31% |
| 2023-12-31 | $-84.64 Million | $-40.68 Million | 0.481x | -77.43% |
| 2022-12-31 | $-45.65 Million | $-97.21 Million | 2.129x | +155.77% |
| 2021-12-31 | $-14.96 Million | $-12.45 Million | 0.832x | +314.30% |
| 2020-12-31 | $254.34 Million | $-98.80 Million | -0.388x | -6.78% |
| 2019-12-31 | $186.01 Million | $-67.67 Million | -0.364x | -18.06% |
| 2018-12-31 | $122.18 Million | $-37.65 Million | -0.308x | +93.67% |
| 2017-12-31 | $3.37 Million | $-16.38 Million | -4.868x | -549.46% |
| 2016-12-31 | $4.42 Million | $-3.31 Million | -0.750x | -- |
About Tectonic Therapeutic, Inc.
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RX… Read more